Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...

Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

The rule proposed by the Biden administration would recognize obesity as a disease that can be treated with the help of the ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...

The stock decline is on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market Data. MariTide has the advantage over rival ...